Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Weekend Morning Brew: Big Tech's $650B AI Bet, Bitcoin Slides
07:37am, Saturday, 07'th Feb 2026
Weekly Market HighlightsMarket breadth was slightly positive on the week, with 4,831 advancers versus 4,694 decliners.Returns were highly skewed, with 491 stoc
Weight-loss drugs to compete on biggest stage with Super Bowl ads
06:07am, Saturday, 07'th Feb 2026
Companies looking to sell weight-loss drugs directly to consumers, including Novo Nordisk's Wegovy, will shell out millions of dollars for celebrity-filled ads during Sunday's Super Bowl with its prom
Heard on the Street: : The obesity-market price war has turned traditional pharma economics upside down.
05:30am, Saturday, 07'th Feb 2026
Prices for GLP-1s are falling fast, forcing companies to adapt.
Tom Gayner's Strategic Moves: FedEx Corp Exit and Portfolio Adjustments
06:00pm, Friday, 06'th Feb 2026
Insights into Tom Gayner (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Tom Gayner (Trades, Portfolio) recently submitted the 13F filing for the fourth q
Market Today: Dow tops 50,000 as chip leaders rebound; Stellantis plunges
05:35pm, Friday, 06'th Feb 2026
Guru Stock PicksTom Gayner has made the following transactions:Reduce in ADI by 12.37%Sold out in ADBEAdd in TMO by 12.54%New position in BRORichard Pzena has m
Generic Ozempic Will Upend the Global Weight-Loss Drug Market
03:45pm, Friday, 06'th Feb 2026
Novo Nordisk is predicting a 13% drop in sales in 2026. As the company's patents on Ozempic expire, could cheaper, generic versions give the company a run for its money?
What's Going On With Novo Nordisk Stock On Friday?
01:51pm, Friday, 06'th Feb 2026
Novo Nordisk A/S (NYSE: NVO) is trading higher on Friday after falling for two consecutive days on lower-than-expected fiscal 2026 guidance and compounding concerns.
Novo Nordisk: The Selloff Is A Blessing In Disguise
01:16pm, Friday, 06'th Feb 2026
Novo Nordisk A/S remains a Strong Buy despite a sharp 2026 outlook-driven selloff, with current pricing reflecting excessive market pessimism. NVO faces near-term headwinds from U.S. pricing pressure,
Why Shares of Novo Nordisk Stock Collapsed This Week
11:31am, Friday, 06'th Feb 2026
Novo Nordisk reported sales growth for 2025, but is guiding for sales and earnings declines in 2026. The company is facing major pricing pressure from the US government, as well as competition in weig
Novo Nordisk Shares Slide 21% After Forecast Cut, Copycat Wegovy Pill Launch
10:41am, Friday, 06'th Feb 2026
Novo Nordisk A/S (NVO) shares have come under renewed pressure after a short-lived rebound earlier this year gave way to a sharp shift in investor sentiment. Af
Hims & Hers falls ~8% premarket after FDA warning on copycat drugs
10:37am, Friday, 06'th Feb 2026
Shares of Hims and Hers Health (HIMS) came under renewed pressure Friday, falling roughly 8% in premarket trading after FDA Commissioner Marty Makary said the age
NVO, LLY Stocks Slide as HIMS Launches $49 Compounded Semaglutide Pill
10:30am, Friday, 06'th Feb 2026
HIMS shakes up the weight loss market with a $49 compounded semaglutide pill, pressuring Novo Nordisk and Eli Lilly shares and sparking FDA and legal pushback.
Major stock indexes opened higher Friday, a day after equities sank amid risk-off sentiment. Still, the Nasdaq and S&P 500 were poised to register sharp weekly losses.
Citi flags lingering risks to Novo despite strong weight-loss portfolio
08:20am, Friday, 06'th Feb 2026
Citi has warned that Novo Nordisk (NYSE:NVO) inability to curb the use of compounded semaglutide may weigh on investor sentiment, despite the strength of its obesity drug portfolio. In a note followin
First Look: Amazon's $200B AI Bet, Tech Rout
07:37am, Friday, 06'th Feb 2026
Stock News Amazon hikes AI capex: Amazon (AMZN) warned 2026 capital expenditures will surge to about $200 billion, focused largely on AWS and AI infrastructure,
